MOTIF BIO PLC/S (NASDAQ:MTFB) was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating in a report released on Wednesday.

Separately, HC Wainwright set a $32.00 price objective on MOTIF BIO PLC/S and gave the stock a “buy” rating in a research note on Tuesday, August 14th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. MOTIF BIO PLC/S currently has an average rating of “Hold” and a consensus price target of $19.50.

Shares of MOTIF BIO PLC/S stock opened at $8.50 on Wednesday. The stock has a market capitalization of $127.51 million, a P/E ratio of -44.74 and a beta of -0.02. The company has a debt-to-equity ratio of -1.58, a current ratio of 0.96 and a quick ratio of 0.96. MOTIF BIO PLC/S has a 1 year low of $7.33 and a 1 year high of $13.75.

MOTIF BIO PLC/S Company Profile

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis.

Read More: How to Invest in Marijuana Stocks

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for MOTIF BIO PLC/S (NASDAQ:MTFB)

Receive News & Ratings for MOTIF BIO PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MOTIF BIO PLC/S and related companies with's FREE daily email newsletter.